Replimune Limited – Trademark Portfolio

Entity Type: 99

Replimune Limited holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 12 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 2 are pending. Notable registered marks include REPLIMUNE. The owner is based in Oxfordshire.

69 Innovation Dr., Milton Park, Abingdon

Oxfordshire OX144RQ , GB

14 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Replimune Limited's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (12 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (12 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Replimune Limited have?

Replimune Limited has 14 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 pending, 6 abandoned, 4 cancelled.

What trademark classes does Replimune Limited file in?

Replimune Limited files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Replimune Limited's most well-known trademarks?

Replimune Limited's registered trademark portfolio includes well-known marks such as REPLIMUNE. These are among 2 currently registered trademarks in the portfolio.

What is Replimune Limited's trademark registration success rate?

Replimune Limited has a 17% trademark registration rate, with 2 out of 12 resolved applications resulting in successful registration. Currently, 2 applications are pending review.